EMA takes further steps to address critical shortages of medicines in the EU
Submitted by Anonymous (not verified) on 24 October 2023 - 14:58
EMA takes further steps to address critical shortages of medicines in the EU
MSSG Solidarity Mechanism
Submitted by Anonymous (not verified) on 24 October 2023 - 14:39
MSSG Solidarity Mechanism
MSSG Toolkit on recommendations on tackling shortages of medicinal products
Submitted by Anonymous (not verified) on 24 October 2023 - 14:38
MSSG Toolkit on recommendations on tackling shortages of medicinal products
Human medicines European public assessment report (EPAR): Actelsar HCT, telmisartan,hydrochlorothiazide, Essential Hypertension, Date of authorisation: 13/03/2013, Revision: 17, Status: Authorised
Submitted by Anonymous (not verified) on 24 October 2023 - 14:14
Human medicines European public assessment report (EPAR): Actelsar HCT, telmisartan,hydrochlorothiazide, Essential Hypertension, Date of authorisation: 13/03/2013, Revision: 17, Status: Authorised
Human medicines European public assessment report (EPAR): Telmisartan Actavis, telmisartan, Hypertension, Date of authorisation: 29/09/2010, Revision: 13, Status: Authorised
Submitted by Anonymous (not verified) on 24 October 2023 - 14:08
Human medicines European public assessment report (EPAR): Telmisartan Actavis, telmisartan, Hypertension, Date of authorisation: 29/09/2010, Revision: 13, Status: Authorised
Idarubicin : List of nationally authorised medicinal products - PSUSA/00001720/202211
Submitted by Anonymous (not verified) on 24 October 2023 - 13:50
Idarubicin : List of nationally authorised medicinal products - PSUSA/00001720/202211
Anastrozole : List of nationally authorised medicinal products - PSUSA/00000210/202208
Submitted by Anonymous (not verified) on 24 October 2023 - 13:45
Anastrozole : List of nationally authorised medicinal products - PSUSA/00000210/202208
Opinion/decision on a Paediatric investigation plan (PIP): Ezeprogind, decision type: , therapeutic area: , PIP number: P/0538/2022
Submitted by Anonymous (not verified) on 24 October 2023 - 13:22
Opinion/decision on a Paediatric investigation plan (PIP): Ezeprogind, decision type: , therapeutic area: , PIP number: P/0538/2022
Opinion/decision on a Paediatric investigation plan (PIP): Messenger RNA encoding Cas9 and single guide RNA targeting the human TTR gene, decision type: , therapeutic area: , PIP number: P/0532/2022
Submitted by Anonymous (not verified) on 24 October 2023 - 13:11
Opinion/decision on a Paediatric investigation plan (PIP): Messenger RNA encoding Cas9 and single guide RNA targeting the human TTR gene, decision type: , therapeutic area: , PIP number: P/0532/2022
Veterinary medicines European public assessment report (EPAR): CaniLeish, Leishmania infantum excreted secreted proteins, Date of authorisation: 14/03/2011, Revision: 2, Status: Withdrawn
Submitted by Anonymous (not verified) on 24 October 2023 - 12:14
Veterinary medicines European public assessment report (EPAR): CaniLeish, Leishmania infantum excreted secreted proteins, Date of authorisation: 14/03/2011, Revision: 2, Status: Withdrawn